What Hims & Hers does

Hims & Hers Health, Inc. (NYSE: HIMS) is a digital health platform founded in 2017 and headquartered in San Francisco that connects consumers in U.S. states where the company operates to licensed telehealth providers for evaluation, prescription, and ongoing clinical care across weight loss, sexual health, hair loss, mental health, dermatology, testosterone optimization, and women's health including menopause. The platform combines a direct-to-consumer e-commerce storefront and mobile applications with pharmacy fulfillment (through Apostrophe Pharmacy, XeCare, Curexa, Red Rock Pharmacy, Gifthealth and others) and laboratory services coordinated via Quest Diagnostics (2,000+ draw sites), GRAIL (multi-cancer early detection), and acquired YourBio Health micro-needle blood collection (TAP/HALO). Its proprietary product line centers on Labs by Hims (130+ biomarkers with personalized Action Plans), the Labs AI care agent that combines frontier language models with an internal clinical knowledge base, and a Weight Loss Membership bundled with branded and generic GLP-1 medications (Wegovy pill/pen, Zepbound KwikPen/vial, Foundayo oral orforglipron, Ozempic, and generic semaglutide) supplied via strategic partnerships with Novo Nordisk, Eli Lilly (LillyDirect), and Canadian suppliers Apotex and Dr. Reddy's.

Revenue is generated through a hybrid model with three primary streams: monthly subscription memberships ($39 first month, then $149/month for Weight Loss Membership; Labs at $349/year), transaction-based medication revenue ($149-$299/month depending on drug), and ancillary lab/ancillary service revenue. Full-year 2025 revenue reached $2.35B (+59% YoY) with adjusted EBITDA of $318M; FY2026 guidance of $2.8-3.0B and a stated FY2030 target of $6.5B revenue / $1.3B adjusted EBITDA anchor expectations. The business is cash-pay (no insurance required) with transparent pricing, supported by paid digital advertising including Super Bowl campaigns and a multi-channel consumer marketing stack. The company has expanded internationally over the past 12 months through the Eucalyptus/Juniper (up to $1.15B), Livewell, ZAVA, and Trybe Labs acquisitions, alongside YourBio Health integration, giving it operations across nine countries and a reported Q1 2026 international revenue line of $78.2M (+1,014% YoY off a small base). Risks and overhangs include an HHS/DOJ referral regarding historical compounded GLP-1 practices, prior Novo Nordisk litigation that was settled into a partnership, and material Q1 2026 growth deceleration to 4% YoY that has triggered reduced FY2026 EBITDA guidance ($275-350M) and a stock that trades meaningfully below its 52-week high.

Name

Hims & Hers

Legal name

Hims & Hers Health, Inc.

Website

https://hims.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hims & Hers Health (NYSE: HIMS) is a U.S.-founded digital health platform offering telehealth consultations, prescription medications, and lab testing services across weight loss (GLP-1s), sexual health, hair loss, mental health, and women's health, serving approximately 2.6 million subscribers across nine countries through direct-to-consumer online and mobile channels.

Ownership category

akta.pro rank

Product category

Consumer Telehealth

NAICS

Offices of Physicians (6211), Pharmacies and Drug Retailers (45611), Medical and Diagnostic Laboratories (6215)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

Keywords

• Telehealth platform
• Online prescription services
• Weight loss medications
• Biomarker lab testing
• Consumer digital health

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Revenue model

1. Subscription Revenue: Recurring monthly membership fees from Weight Loss Membership ($39 first month, $149/month thereafter) and general telehealth subscriptions. Provides access to providers, clinical services, and medication prescriptions.
2. Medication Sales: Transaction revenue from prescription medications including GLP-1 drugs (Wegovy, Zepbound, Ozempic, Foundayo). Medication costs billed separately from membership fees. Prices range from $149-$299/month depending on medication.
3. Laboratory Testing Services: Lab testing services coordinated through platform including biomarker panels (130+ markers), cancer screening, and at-home collection kits. Processed by Quest Diagnostics and GRAIL.
4. Platform Services: Revenue from providing telehealth infrastructure connecting patients with providers across weight loss, sexual health, mental health, and dermatology. Estimated $2.35B in full-year 2025 revenue.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Hims & Hers is a consumer telehealth platform that connects patients with state-licensed providers for online evaluation, prescription, and ongoing management of conditions including weight loss (GLP-1 medications such as Wegovy, Zepbound, Foundayo, and Ozempic), sexual health, hair loss, mental health, testosterone deficiency, and dermatology. Customers subscribe to category-specific memberships, receive FDA-approved medications shipped from partnered pharmacies, and can order comprehensive at-home lab testing (130+ biomarkers, multi-cancer screening). Revenue is generated through monthly subscription membership fees combined with per-prescription and per-test transaction charges.

Product overview

Hims & Hers operates a platform-plus-subscriptions architecture combining telehealth consultations, prescription medications, and health monitoring services. The core offering is the Hims & Hers telehealth platform providing access to providers across weight loss, sexual health, hair loss, mental health, and testosterone categories. Key product lines include: (1) Weight Loss Program with GLP-1 medications (Wegovy, Zepbound, Foundayo, Ozempic) offered through a Weight Loss Membership subscription; (2) Labs by Hims with 130+ biomarker tests and the GRAIL-based Multi-Cancer Test; (3) prescription treatments for erectile dysfunction, hair loss, and mental health; (4) the subscriber benefits program offering partner wellness discounts. The company has expanded internationally through acquisitions of Eucalyptus/Juniper (Australia, UK, Germany, Japan), Livewell (Canada), and YourBio Health (blood sampling technology), and domestically through Apostrophe (teledermatology). All services are provided through state-licensed providers via subscription models with medication billed separately.

Differentiator

Problem solved

Functional benefit

Brands

• Juniper: Weight management platform acquired through Eucalyptus, operating in UK, Germany, Australia, and Japan
• Pilot
• ZAVA
• Livewell
• Apostrophe
• Labs by Hims

Products and services

• Hims Weight Loss Program Subscription-based telehealth weight-loss program offering access to FDA-approved GLP-1 medications including Wegovy (pill and pen), Zepbound, Ozempic, and Foundayo, combined with personalized treatment plans, unlimited Care Team messaging, and nutrition guidance.
• Hims Weight Loss Membership Monthly subscription ($39 first month, $149/month thereafter) granting access to weight-loss clinical care, monthly check-ins, medication adjustments, provider messaging, and the Hims & Hers Weight Loss community.
• Labs by Hims Annual subscription lab-testing service covering 130+ biomarkers across heart, metabolic, hormone, thyroid, kidney, liver, immune, nutrient, blood, and inflammation categories, with doctor-developed Action Plans, 6-month retesting, and 24/7 provider messaging.
• Multi-Cancer Test by Galleri Annual add-on blood test screening for signal associated with 50+ cancer types using GRAIL's methylation-based multi-cancer early detection technology, with Cancer Signal Origin prediction and provider follow-up.
• Sexual Health Treatments Telehealth consultations and prescription treatments for erectile dysfunction (Sildenafil, Tadalafil, Cialis) and premature ejaculation (sertraline), shipped discreetly to customers.
• Hair Loss Treatments Prescription and OTC treatments for male-pattern hair loss, including oral and topical Finasteride and Minoxidil solution, marketed under the Hims brand.
• Testosterone by Hims Testosterone optimization program for men featuring enclomiphene, at-home lab testing for T levels, and supplements, targeting low-testosterone symptoms.
• Mental Health / Psychiatry Telehealth psychiatry services providing prescription medications for depression and anxiety, including Sertraline (generic Zoloft) and Escitalopram (generic Lexapro).
• Hims & Hers Benefits Subscriber benefits program offering discounts and free trials across partner wellness brands including Natural Cycles, MyFitnessPal, Flo Health, Dexcom Stelo, HelloFresh, Factor, Ladder, PVOLVE Studios, and iFIT spanning nutrition, fitness, women's health, and metabolic monitoring.
• Wegovy Pill FDA-approved once-daily oral GLP-1 medication (semaglutide) for weight management, priced from $149/month, with up to 20% body-weight loss and an SNAC molecule for increased absorption.
• Wegovy Pen FDA-approved once-weekly GLP-1 injection (semaglutide) for weight management, priced from $199/month, with up to 25% body-weight loss and available in dosages from 0.25mg to 7.2mg.
• Zepbound KwikPen FDA-approved once-weekly GLP-1/GIP injection (tirzepatide) for weight loss, priced at $299/month, with up to 21% body-weight loss and additional FDA approval for moderate-to-severe obstructive sleep apnea.
• Zepbound Vial FDA-approved once-weekly GLP-1 injection (tirzepatide) in vial format for self-administration with pre-filled syringe, priced at $299/month.
• Foundayo FDA-approved daily GLP-1 pill (orforglipron) for weight loss, priced from $149/month, with 11.1% body-weight loss and no food, water, or timing restrictions due to small-molecule absorption design.
• Ozempic Pill FDA-approved once-daily oral GLP-1 medication (semaglutide) for Type 2 diabetes, priced from $149/month, which may be prescribed off-label for weight management.
• Generic Semaglutide Canada Generic semaglutide offering for Canadian customers at $149/month CAD, including personalized care plans and Care Team support, supplied through partnerships with Apotex and Dr. Reddy's Laboratories.
• Labs AI AI care agent embedded in the platform that helps customers interpret biomarker lab results across up to 130 biomarker tests, combining frontier language models with the company's clinical knowledge base to identify health patterns and recommend when to consult licensed clinicians.

Quantifiable outcome

• Lose up to 25% body weight with Wegovy
• +6 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature3 records

Partnerships

17 partnerships are on record, tiered minor, core and strategic.

• Natural CyclesminorGTM or Marketing Partner · 28 May 2026Women's health platform added to subscriber benefits program. Offers 28 days complimentary access for Hims & Hers subscribers as part of expanded wellness partner ecosystem.
• Flo HealthminorGTM or Marketing Partner · 28 May 2026Women's health app added to subscriber benefits. Offers 40% discount for Hims & Hers subscribers as part of expanded wellness partner ecosystem.
• MyFitnessPalminorGTM or Marketing Partner · 28 May 2026Fitness and nutrition tracking app added to subscriber benefits program supporting holistic wellness and GLP-1 treatment programs.
• Dexcom (Stelo)minorGTM or Marketing Partner · 28 May 2026Metabolic monitoring partner added to subscriber benefits. Continuous glucose monitoring integration for subscribers undergoing GLP-1 treatment.
• HelloFresh, Factor, Ladder, PVOLVE Studios, iFITminorGTM or Marketing Partner · 28 May 2026Nutrition, fitness, and wellness brands added to subscriber benefits program. Offers free trial periods and subscriber discounts across fitness and metabolic monitoring.
• Apotex Inc.coreStrategic or Co-development Partner · 21 May 2026Generic semaglutide supplier in Canada following Health Canada approval. Apotex's generic Ozempic shipping to wholesalers and pharmacies nationwide. Hims first platform to bring generic GLP-1 to eligible Canadians.
• Dr. Reddy's LaboratoriesstrategicStrategic or Co-development Partner · 28 April 2026Generic Ozempic manufacturer in Canada. Dr. Reddy's received Health Canada approval for generic semaglutide on April 28, enabling Canadian generic GLP-1 availability.
• Eli LillycoreStrategic or Co-development Partner · 23 April 2026Partnership enabling access to Eli Lilly GLP-1 medications including Zepbound, Mounjaro, and Foundayo through LillyDirect pharmacy. Platform connects customers with self-pay pricing for Lilly's weight-loss drugs.
• Novo NordiskcoreStrategic or Co-development Partner · 9 March 2026Strategic partnership for distribution of FDA-approved GLP-1 medications including Wegovy and Ozempic through Hims & Hers telehealth platform. Following legal dispute resolution, Novo Nordisk authorized distribution partnership. Hims became one of largest U.S. telehealth providers of weight-loss drugs through this channel.
• EucalyptuscoreOEM/ Whitelabel/ Licensing Partner · 19 February 2026Acquisition valued at up to $1.15 billion ($240M upfront, remainder in deferred and earnout payments through early 2029). Eucalyptus brings 775,000+ customers across 5 countries including Australia, UK, Germany, Japan. Parent company of Juniper weight management brand.
• LivewellstrategicOEM/ Whitelabel/ Licensing Partner · 4 December 2025Acquisition of Canadian digital health platform enabling entry into Canada market. Company launched operations in Canada following acquisition with plans to introduce weight loss program in 2026.
• YourBio Health, Inc.strategicTechnology or Integration · 3 December 2025Acquisition of Boston-based blood sampling technology company. Deal expected to close early 2026. Enhances product portfolio with pain-free micro-needle blood collection devices using patented TAP and HALO systems.
• ApostrophestrategicOEM/ Whitelabel/ Licensing Partner · 24 June 2021Acquisition of teledermatology platform expanding dermatology capabilities. Includes clinical platform and dermatology expert team for personalized dermatology treatments.
• GRAIL, Inc.coreStrategic or Co-development PartnerPartnership for multi-cancer early detection test (Galleri). Hims & Hers offers screening for 50+ cancer types through single blood draw using GRAIL's methylation-based detection technology.
• Quest DiagnosticscoreStrategic or Co-development PartnerLaboratory services partnership for biomarker testing. Customers schedule blood draws at 2,000+ Quest Diagnostics locations nationwide through Hims & Hers app.
• ZAVAstrategicOEM/ Whitelabel/ Licensing PartnerEuropean digital health company acquisition expanding presence into UK and Germany. Contributed to international revenue surge to $78M in Q1 2026.
• Gifthealth, Inc.minorChannel Partner/ Reseller/ DistributorAlternative pharmacy partner for manufacturer self-pay pharmacy solutions when medications unavailable through primary pharmacies. Handles billing, fulfillment, and customer service for specific prescriptions.

Scale indicators17 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Ro: Direct-to-consumer men's and women's telehealth platform offering consultations, prescriptions and pharmacy fulfillment across ED, hair loss, weight loss, and mental health. Most direct competitor to Hims given similar D2C model, cash-pay positioning, and treatment categories.
• Thirty Madison: Multi-condition D2C telehealth platform operating Keeps (hair), Nurx (women's health, dermatology, mental health) and Cove (migraine). Closely comparable to Hims in vertical-by-vertical telehealth subscription model and cash-pay pharmacy distribution.
• Lemonaid Health: Telehealth platform offering online consultations and prescription medications across mental health, dermatology, sexual health and chronic conditions. Comparable D2C pharmacy-integrated telehealth model with broad condition coverage.

Broad incumbents

• Teladoc Health: Largest US telehealth incumbent operating across general medical, chronic care, mental health, and dermatology. Pivots to consumer-facing BetterHelp and primary care segments; broader/established player with overlapping but more enterprise/B2B-skewed business model versus Hims' D2C focus.
• Amwell: Enterprise telehealth platform serving health systems, health plans, and employers. Provides complementary infrastructure rather than direct consumer pharmacy but competes for telehealth mindshare and partnerships with health plans/payers.
• GoodRx: Cash-pay prescription marketplace and telehealth platform providing transparent medication pricing. Direct functional overlap with Hims' cash-pay pharmacy/medication fulfillment approach, particularly for self-pay GLP-1 users, though more retail-pharmacy focused.
• WW (WeightWatchers): Established weight management subscription platform that expanded into GLP-1 medication access through Sequence acquisition. Competes head-to-head with Hims in cash-pay weight loss/GLP-1 category.

Emerging players

• K Health: AI-powered primary care telehealth platform offering subscriptions for ongoing clinical care, mental health, and prescription services. Comparable AI-first telehealth positioning and cash-pay membership model.
• Noom: Subscription-based weight management and behavior change app now offering GLP-1 medication access. Direct competitor in cash-pay weight loss category, combining digital coaching with prescription fulfillment.
• Cerebral: Direct-to-consumer mental health telehealth platform offering evaluations and prescriptions for anxiety, depression, and ADHD. Adjacent D2C telehealth competitor especially in Hims' psychiatry/mental health service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/wearehims
• LinkedInlinkedin.com/company/hims
• Instagraminstagram.com/hims
• Facebookfacebook.com/wearehims

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries5 records

Funding overview

Funding rounds9 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hims & Hers